Please login to the form below

Not currently logged in
Email:
Password:

Pfizer pays $680m to buy ADHD drug developer NextWave

Portfolio includes once-daily Quillivant XR

Pfizer has agreed to buy NextWave Pharmaceuticals for $680m in a deal that would bring it a franchise in drugs to treat attention deficit hyperactivity disorder (ADHD).

The pharma giant took a $20m option to merge with NextWave earlier this year and has now followed that up with a full acquisition offer of $255m, plus sales milestones of up to $425m. Pfizer said the transaction is expected to close later this year.

The primary asset held by NextWave is Quillivant XR (methylphenidate HCl), an extended-release ADHD drug in a child-friendly liquid formulation that can be given just once a day before school. 

The product fills a void in ADHD treatment as it provides an alternative to tablets or capsules for patients who have difficulty taking them, but also provides cover for the entire day with a single dose, thereby avoiding any stigma that may be associated with taking medicines in school.

The product was developed in partnership with drug delivery specialist Tris Pharma and has just been granted marketing approval in the US, with NextWave holding exclusive marketing rights in North America.

Quillivant XR's clinical profile should help it make inroads into a global ADHD market estimated to be worth around $4bn and growing at 8 per cent a year, according to GlobalData estimates.

The market in the US has been dominated for some time by Shire - with products such as Daytrana (methylphenidate; now divested to Noven Pharma), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) - and Johnson & Johnson with its Concerta (methylphenidate) product.

Generic versions of older ADHD drugs such as Shire's Adderall XR (mixed amphetamine salts) are starting to change the dynamics of the market, however. Meanwhile, with even second-generation therapies such as Concerta now facing patent expiry, newer products will need clear advantages - as well as marketing muscle - to differentiate themselves in the marketplace.

In addition to Quillivant XR, NextWave is developing a chewable tablet formulation of methylphenidate - codenamed NWP09 - that is due to be filed for approval in 2013.

23rd October 2012

From: Sales

Share

Tags

Related Hub content

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Waggener Edstrom

Waggener Edstrom’s global and European healthcare hub is based in London, and works with experienced teams across the globe; teams...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...